[The functional status of the sympathoadrenal system in hypertension patients being treated with captopril and dalargin].
The level of urinary excretion of catecholamines (CA) and their precursors was studied in 87 patients with stage I, II hypertensive disease (HD). Three groups were formed depending on the therapy option: group I comprised stage I HD patients in whom endonasal dalargin electrophoresis (EDE) was instituted, groups II and III were patients with stage II HD who were given a complex therapy with captopril plus EDE and monotherapy with captopril respectively. EDE led to a decline in the functional activity of the sympathoadrenal system (SAS) in stage I HD patients and potentiated a hypotensive effect of captopril resulting in diminution of excretion of norepinephrine. Captopril monotherapy failed to have an effect on the SAS condition.
Kuriata
A V
AV
D000311:Adrenal Glands / Q000187:drug effects* / Q000503:physiopathology; D000328:Adult; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002216:Captopril / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D016308:Enkephalin, Leucine-2-Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D008875:Middle Aged; D013564:Sympathetic Nervous System / Q000187:drug effects* / Q000503:physiopathology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D016308:Enkephalin, Leucine-2-Alanine; D002216:Captopril; C040996:enkephalin-Leu, Ala(2)-Arg(6)-